Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lonza Biologics

Division of Lonza Group Ltd.
www.lonzabiologics.com

Latest From Lonza Biologics

Cell And Gene Therapy Manufacturing: Catalent Snaps Up MaSTherCell

Consolidation and acquisitions among contract manufacturers of cell and gene therapies is a growing trend, as Catalent acquires Belgium- and US-based MaSTherCell Global for $315m, and other cell and gene therapy manufacturers address capacity shortages.

M & A Regenerative Medicine

Rising Costs, Price Pressure Usher In Uncertain Year Of The Rat In China

Once the world's factory, China has seen costs inch up while drug prices are being cut deeply by centralized procurement schemes. As uncertainties mount, companies need to focus on improving process and scale-up technology, suggested industry observers at a JPM panel discussion on innovation and market access challenges.

China Pricing Debate

Celltrion Enlists Lonza To Help Make Its Remsima

Lonza will help Celltrion to satisfy increasing global demand for biosimilar infliximab after signing a deal to manufacture the drug substance for Remsima.

Manufacturing Deals

WuXi Biologics To Be ‘World’s No.1’ Biologics Maker

WuXi Biologics is aiming high to become the world’s biggest biologics manufacturer within five years after seeing strong confidence from capital markets in its growth potential and a boost from its new biologics manufacturing facility. The Chinese company plans on more investment in early 2018 to prepare for an expected biologics surge in China, its chief executive tells Scrip.

Biologics Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
    • Synthesis Technologies, Production Processes
  • Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • UK
  • Parent & Subsidiaries
  • Lonza Group Ltd.
  • Senior Management
  • Markus Gemuend, Pres.
  • Contact Info
  • Lonza Biologics
    Phone: (44) 1753 777000
    228 Bath Rd.
    Slough, SL1 4DY
    UK
UsernamePublicRestriction

Register